Quick Answer
10x Genomics, Inc. reported Earnings Per Share Diluted of $0.35 (loss) per share for the year ending 2025.
- 10x Genomics, Inc. showed an increase of +77.0% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from 10x Genomics, Inc.'s annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $0.22 (loss) per share | Q2 2020: $0.41 (loss) per share | Q3 2020: $0.65 (loss) per share | Q1 2021: $0.11 (loss) per share | Q2 2021: $0.10 (loss) per share | Q3 2021: $0.15 (loss) per share | Q1 2022: $0.38 (loss) per share | Q2 2022: $0.57 (loss) per share | Q3 2022: $0.37 (loss) per share | Q1 2023: $0.44 (loss) per share | Q2 2023: $0.53 (loss) per share | Q3 2023: $0.79 (loss) per share | Q1 2024: $0.50 (loss) per share | Q2 2024: $0.32 (loss) per share | Q3 2024: $0.30 (loss) per share | Q1 2025: $0.28 (loss) per share | Q2 2025: $0.28 per share | Q3 2025: $0.22 (loss) per share.
- Over the full 7 years of available data (2019 to 2025), 10x Genomics, Inc.'s Earnings Per Share Diluted has grown by 56.3%.
- Historical annual values: Fiscal year 2025: $0.35 (loss) per share | Fiscal year 2024: $1.52 (loss) per share | Fiscal year 2023: $2.18 (loss) per share | Fiscal year 2022: $1.46 (loss) per share | Fiscal year 2021: $0.53 (loss) per share | Fiscal year 2020: $5.37 (loss) per share | Fiscal year 2019: $0.80 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: